Albert Font

3.6k total citations
75 papers, 1.7k citations indexed

About

Albert Font is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Albert Font has authored 75 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 41 papers in Oncology and 20 papers in Surgery. Recurrent topics in Albert Font's work include Prostate Cancer Treatment and Research (33 papers), Bladder and Urothelial Cancer Treatments (13 papers) and Urinary and Genital Oncology Studies (12 papers). Albert Font is often cited by papers focused on Prostate Cancer Treatment and Research (33 papers), Bladder and Urothelial Cancer Treatments (13 papers) and Urinary and Genital Oncology Studies (12 papers). Albert Font collaborates with scholars based in Spain, United Kingdom and United States. Albert Font's co-authors include Vicenç Ruiz de Porras, Rafael Rosell, Johann S. de Bono, Mariano Monzó, Rafael Rosell, Àlex Pifarré, Isabel Ojanguren, Joan Carles, Ruth Riisnaes and Daniel Nava Rodrigues and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Albert Font

70 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Albert Font Spain	22	874	720	498	381	318	75	1.7k
Dinesh Chandra Doval India	24	673 0.8×	1.2k 1.6×	323 0.6×	428 1.1×	367 1.2×	101	1.9k
Barbara Melosky Canada	28	1.1k 1.3×	1.3k 1.8×	388 0.8×	334 0.9×	129 0.4×	116	2.0k
Ana C. Xavier United States	13	1.1k 1.3×	1.1k 1.5×	518 1.0×	333 0.9×	123 0.4×	51	1.8k
Katsuhiro Masago Japan	25	1.5k 1.7×	1.2k 1.6×	453 0.9×	324 0.9×	148 0.5×	119	2.1k
Dean Lim United States	24	417 0.5×	971 1.3×	706 1.4×	330 0.9×	461 1.4×	72	2.1k
Desirée Hao Canada	23	633 0.7×	842 1.2×	469 0.9×	201 0.5×	282 0.9×	90	1.5k
Jacob J. Adashek United States	24	506 0.6×	816 1.1×	338 0.7×	416 1.1×	195 0.6×	106	1.5k
Enrique Gallardo Spain	18	621 0.7×	480 0.7×	500 1.0×	315 0.8×	571 1.8×	90	1.6k
Juergen Wolf Germany	22	914 1.0×	1.0k 1.4×	630 1.3×	282 0.7×	127 0.4×	92	1.8k
R. J. Amato United States	20	943 1.1×	588 0.8×	779 1.6×	442 1.2×	816 2.6×	68	2.0k

Countries citing papers authored by Albert Font

Since Specialization

Citations

This map shows the geographic impact of Albert Font's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Font with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Font more than expected).

Fields of papers citing papers by Albert Font

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Font. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Font. The network helps show where Albert Font may publish in the future.

Co-authorship network of co-authors of Albert Font

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Font. A scholar is included among the top collaborators of Albert Font based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Font. Albert Font is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Font, Albert, et al.. (2025). Tumor-Educated Platelets in Urological Tumors: A Novel Biosource in Liquid Biopsy. International Journal of Molecular Sciences. 26(8). 3595–3595.

Rodríguez-Moreno, Juan Francisco, Guillermo de Velasco, Carlos Álvarez-Fernández, et al.. (2025). Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial. Clinical Cancer Research. 31(9). 1644–1656.

Porras, Vicenç Ruiz de, et al.. (2024). E-learning pills on immunotherapy in urothelial carcinoma: The E-PIMUC program for continuing medical education. Frontiers in Pharmacology. 15. 1380954–1380954. 1 indexed citations

Porras, Vicenç Ruiz de, Adrià Bernat‐Peguera, Natàlia Jiménez, et al.. (2024). Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer. Frontiers in Pharmacology. 15. 3 indexed citations

Climent, Miguel Ángel, Albert Font, Ignacio Durán, et al.. (2022). A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. European Journal of Cancer. 175. 110–119. 9 indexed citations

Sánchez-Moral, Lidia, et al.. (2022). Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?. Cancers. 14(2). 440–440. 29 indexed citations

Jiménez, Natàlia, Òscar Reig, Mercedes Marín‐Aguilera, et al.. (2022). Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel. Cancers. 14(19). 4757–4757. 8 indexed citations

Porras, Vicenç Ruiz de, et al.. (2022). Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions. Critical Reviews in Oncology/Hematology. 178. 103795–103795. 10 indexed citations

Font, Albert, Montserrat Domènech, Xavier Elias, et al.. (2022). Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer. World Journal of Urology. 40(11). 2627–2634. 1 indexed citations

10.

España, Samuel, Núria Sala, Maria-Pilar Barretina-Ginesta, et al.. (2020). PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. SHILAP Revista de lepidopterología. 2 indexed citations

11.

Font, Albert, Montserrat Domènech, Raquel Benítez, et al.. (2020). Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy. Cancers. 12(7). 1784–1784. 34 indexed citations

12.

Piulats, Josep M., Núria Sala, A. Boladeras, et al.. (2020). 667P Impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) on overall survival (OS) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel (D) plus androgen-deprivation therapy (ADT). Annals of Oncology. 31. S537–S537. 2 indexed citations

13.

Jiménez, Natàlia, Òscar Reig, Giancarlo Castellano, et al.. (2020). 1971P Neuroendocrine (NE) expression profiling in non-castrate tumours is associated with poor therapy benefit and adverse clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients. Annals of Oncology. 31. S1107–S1107.

14.

Bono, Johann S. de, Ugo De Giorgi, Daniel Nava Rodrigues, et al.. (2018). Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clinical Cancer Research. 25(3). 928–936. 227 indexed citations

15.

Carles, Joan, Enrique Gallardo, Montserrat Domènech, et al.. (2018). Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 103(2). 344–352. 5 indexed citations

16.

Bono, Johann S. de, Ugo De Giorgi, Christophe Massard, et al.. (2016). PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 27. vi243–vi243. 40 indexed citations

17.

Marín‐Aguilera, Mercedes, Jordi Codony‐Servat, Òscar Reig, et al.. (2014). Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. Molecular Cancer Therapeutics. 13(5). 1270–1284. 123 indexed citations

18.

Chabrera, Carolina, et al.. (2014). A Decision Aid to Support Informed Choices for Patients Recently Diagnosed With Prostate Cancer. Cancer Nursing. 38(3). E42–E50. 49 indexed citations

19.

Mellado, Begoña, Albert Font, Antonio Alcaraz, et al.. (2009). Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. British Journal of Cancer. 101(8). 1248–1252. 39 indexed citations

20.

Sánchez, José Miguel, Carmen Balañá, Albert Font, et al.. (2002). Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Lung Cancer. 38(3). 309–315. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact